UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample
Ecstasy use was also associated with significantly higher odds of better self-reported overall health.
A comparative study of the harms of nitrous oxide and poppers using the MCDA approach
On the overall harm scale, N2O scored 6, just above magic mushrooms (psilocybin) while ‘poppers’ scored 5. Together these are the three lowest drugs on the overall harm scale.
Interdisciplinary Conference on Psychedelic Research 2022
The question on everybody’s lips was – ‘how can we implement psychedelics into our pre-existing healthcare systems safely, legally, and responsibly?’.
Psychedelics therapeutics: What we know, what we think, and what we need to research
Psychedelic therapy is perhaps the most exciting new development in psychiatry.
Towards an understanding of psychedelic-induced neuroplasticity
The focus of this review is on answering specific questions about the effects of psychedelics on neuroplasticity.
Facing death, returning to life: A qualitative analysis of MDMA-assisted therapy for anxiety associated with life-threatening illness
Participant narratives also showed a reconnection to life and greater emotional resilience in response to trauma and medical relapse.
The use of psychedelics in the treatment of medical conditions: An analysis of currently registered psychedelics studies in the American drug trial registry
There appears to be a recent uptrend in registered clinical trials studying psychedelics, which is similar to the recent increase in overall trials registered.
'Magic' of psychedelics: Easing the trauma of terminal illness
A growing body of evidence shows that psilocybin is safe and can relieve symptoms of depression and end-of-life demoralization in people with cancer and other life-threatening conditions.
The safety and efficacy of psychedelic-assisted therapies for older adults: Knowns and unknowns
Given the potential of psychedelic compounds to benefit older adults, more research is needed to establish safety and efficacy among older adults
Arketamine, a new rapid-acting antidepressant: A historical review and future directions
This study was designed to review the brief history of the novel antidepressant arketamine, the molecular mechanisms underlying its antidepressant actions, and future directions.
Psychedelic Alpha Bulletin – A deep dive into psilocybin for alcohol use disorder
Heavy drinking days decreased by about 80% among those in the psilocybin group.
Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness A randomized, double-blind, placebo-controlled Phase II study
LSD produced long-lasting and notable reductions of anxiety and comorbid depression symptoms up to 16 weeks.
Psychedelic forum member preferences for carer experience and consumption behavior: Can “trip sitters” help inform psychedelic harm reduction services?
Psychedelic harm reduction services should consider how remote workers could be employed. There is a clear demand for remote psychedelic care services and to our knowledge this has not yet been explored.